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Background: Leucine-rich repeat kinase 2 (LRRK2) is a gene in which a mutation causes Parkinson’s disease (PD),
and p53 is a prototype tumor suppressor. In addition, activation of p53 in patient with PD has been reported by
several studies. Because phosphorylation of p53 is critical for regulating its activity and LRRK2 is a kinase, we tested
whether p53 is phosphorylated by LRRK2.
Results: LRRK2 phosphorylates threonine (Thr) at TXR sites in an in vitro kinase assay, and the T304 and T377 were
identified as putative phosphorylated residues. An increase of phospho-Thr in the p53 TXR motif was confirmed in
the cells overexpressing G2019S, and human induced pluripotent stem (iPS) cells of a G2019S carrier. Interactions
between LRRK2 and p53 were confirmed by co-immunoprecipitation of lysates of differentiated SH-SY5Y cells.
LRRK2 mediated p53 phosphorylation translocalizes p53 predominantly to nucleus and increases p21WAF1/CIP1
expression in SH-SY5Y cells based on reverse transcription-polymerase chain reaction and Western blot assay results.
The luciferase assay using the p21WAF1/CIP1 promoter-reporter also confirmed that LRRK2 kinase activity increases
p21 expression. Exogenous expression of G2019S and the phosphomimetic p53 T304/377D mutants increased
expression of p21WAF1/CIP1 and cleaved PARP, and cytotoxicity in the same cells. We also observed increase of p21
expression in rat primary neuron cells after transient expression of p53 T304/377D mutants and the mid-brain
lysates of the G2019S transgenic mice.
Conclusion: p53 is a LRRK2 kinase substrate. Phosphorylation of p53 by LRRK2 induces p21WAF1/CIP1 expression and
apoptosis in differentiated SH-SY5Y cells and rat primary neurons.Background
Leucine-rich repeat kinase 2 (LRRK2) is one of the
Parkinson’s disease (PD)-causative genes along with
SNCA (α-synuclein), PARK2 (Parkin), DJ-1 and PINK1
[1, 2]. LRRK2 contains both kinase and GTPase do-
mains [3–5] whose activities are critical for signal
transduction. Moreover, the G2019S pathogenic muta-
tion [6] increases kinase activity [7, 8] and affects
various pathogenic phenotypes such as increased
neuronal cytotoxicity and protein aggregation [7, 9, 10],
decreased neurite length [11, 12] and changes in the* Correspondence: sonih@wku.ac.kr; wseolha@gmail.com
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inhibition of kinase activity rescues pathogenic pheno-
types, such as neurocytotoxicity and defective neurite
outgrowth [14]. Because of the relevance of LRRK2
kinase activity to PD pathogenesis, LRRK2 has
emerged as a therapeutic target of PD, and the effort
to identify LRRK2 kinase substrates and chemical in-
hibitors has intensified [15–21]. To date, several di-
verse proteins have been reported as potential LRRK2
kinase substrates. Some examples are β-tubulin [22],
ArfGAP1 [23, 24], tau [25], members of the mitogen-
activated protein kinase kinase family [26], eukaryotic
initiation factor 4E-binding protein (4E-BP; [27]),
Akt1 [28], ribosomal protein s15 [19], endophilin A
[18], Rab5 [21], Bcl-2 [29] and Snapin [20]. It is un-
clear whether these proteins are actual physiologicalistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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roles in vesicle trafficking, autophagy, mitochondrial
dysfunction, and inflammation [13, 18, 30–32]. In
addition, one study identified several ribosomal pro-
teins as LRRK2 kinase substrates using an unbiased
proteomics suggesting that LRRK2 is a translational
regulator [19] along with a previous 4E-BP study [27].
p53 is encoded by TP53, and is a well-known tumor
suppressor that is mutated in numerous types of tumor
cells [33]. p53 is a transcription factor that is degraded
through interacting with MDM2 under normal condi-
tion, but p53 is phosphorylated at specific residues, be-
come stabilized and resistant to its own degradation
during exposure to genomic or other stressors [34, 35].
Phosphorylated p53 enhances its nuclear retention,
resulting in increased p53 binding to its target sequences
and activation of target genes, most of which function in
apoptosis or cell growth arrest [36].
p53 has been postulated to contribute to PD pathogen-
esis. For example, PD toxins, such as MPTP, rotenone,
and 6-hydroxydopamine activate p53 [37]. In addition, PD
causative genes, such as Parkin, DJ-1, and α-synuclein
affect p53 expression or its activity [37–39].
Here, we report that LRRK2 phosphorylates p53,
which could be another clue to the relationship be-
tween p53 and PD pathogenesis.
Results
LRRK2 phosphorylates p53 in vitro
We were interested in identifying novel LRRK2 kinase
substrates. Because of p53 activation in PD brains, we
tested whether LRRK2 phosphorylates p53 using E. coli-
expressed recombinant p53 protein and [γ-32P]ATP in
an in vitro kinase assay. The GST-ΔN LRRK2 wild type
(WT) phosphorylated p53 significantly and the corre-
sponding G2019S (GS) and kinase-dead D1994A (DA)
mutant proteins enhanced and nullified p53 phosphoryl-
ation, respectively, as expected (Fig. 1A-a). The GST-ΔN
LRRK2 was used instead of the full length WT because
the former exhibited stronger kinase activity than the
latter (data not shown).
Because the TXR motif is suggested as a conserved
LRRK2 phosphorylation site [20, 40–42], we checked
whether such sites are present in p53. We found three
sites: 211TFR, 304TKR, and 377TSR (numbers indicate
position of threonine in human p53 protein, Fig. 1c). To
investigate whether p53 is phosphorylated on these sites,
we tested to see if phosphorylated p53 was detectable by
Western blot with anti-phospho-TXR antibody (p-TXR).
p-TXR is a commercial phospho-specific antibody that
recognizes a phosphorylated threonine residue in the
TXR motif. This antibody was shown to detect a specific
phosphorylated threonine (T1410) in the LRRK2 TXR
motif (TQR) after autophosphorylation of LRRK2 [41].The Western blot result using the p-TXR antibody after
the in vitro kinase assay detected phosphorylated p53
proteins after incubation with LRRK2 WT or GS, but
not with DA. This is similar to the autoradiogram shown
in Fig. 1A-a, suggesting that p53 was phosphorylated at
threonines in the TXR sites (Fig. 1A-b). The in vitro
kinase assay was carried out with p53 WT and the mu-
tant proteins to detect the p53 phosphorylation sites.
We first used the 1–293 deletion mutant of p53, in
which the C-terminus of 100 amino acids has been de-
leted. As shown in Fig. 1B-b, the p-TXR antibody de-
tected no signal in the 1–293 proteins after incubation
with LRRK2, whereas it detected strong signal in the
T387A, a positive control, suggesting that TXR phosphor-
ylation sites are present on the C-terminal 100 amino
acids. When we used the T304A, T377A, and T304/377A
point mutant proteins in which the indicated threonine
residues were mutated to alanine, the p-TXR antibody
signal decreased in both T304A and T377A mutants
and disappeared in the double-mutant T304/377A pro-
tein, suggesting that these sites are phosphorylated by
LRRK2 (Fig. 1B-b). In contrast to the Western blot
data, autoradiography revealed residual phosphoryl-
ation of the T304/377A protein, although radioactivity
decreased by up to 50 % when compared to that of the
WT (Fig. 1B-a). This residual activity was similar to
the level observed in the 1–293 deletion protein, sug-
gesting that although LRRK2 mainly phosphorylates
p53 via the T304 and T377 sites, there may be add-
itional LRRK2-mediated phosphorylation sites in the
N-terminal 293 amino acid region (Fig. 1B-a). The kin-
ase assay with the recombinant LRRK2 WT full length
yielded a similar result (Additional file 1: Figure S1A).
The p-TXR antibody specificity was confirmed by two
separate results. First, p53 WT or the T304/377A double-
mutant was not recognized by the p-TXR antibody
(Fig. 1A-b & B-b). Second, moesin, an LRRK2 kinase sub-
strate, was detected by the p-TXR antibody after the moe-
sin was used as substrate in an in vitro kinase assay
(Additional file 1: Figure S1B). Moesin has been reported
to be phosphorylated by LRRK2 at T558 in TLR site by
LRRK2 [40].
We applied MS to clearly determine the p53 phos-
phorylated residues. The p53 protein was used for the
MS analysis with or without co-incubation of the LRRK2
G2019S recombinant proteins. However, two such trials
failed to detect a positive signal.
LRRK2 interacts with and phosphorylates p53 in
physiological condition
Next, we tested whether LRRK2 and p53 interact with
each other in physiological condition. The human neuro-
blastoma SH-SY5Y cell line is one of the most widely used
dopaminergic cellular models with differentiation by
Fig. 1 LRRK2 phosphorylates p53 at T304 and T377 in an in vitro kinase assay. A. Recombinant GST-ΔN LRRK2 phosphorylates recombinant human
p53 WT (A) or mutant proteins B. The recombinant p53 protein was subjected to the in vitro kinase assay with cold ATP (b − d) or γ32P-ATP
(a) and analyzed by Western blot with the indicated antibodies (b, p-TXR: phospho-TXR; c, LRRK2: MJFF2; d, p53:DO1) or autoradiography (a).
WT: wild type, GS: G2019S, DA: D1994A. C. A schematic diagram of the p53 functional domains and location of the human p53 TXR motifs.
Thr 387 which was used as a control was also shown. Numbers below the gel figures are the densitometric results for each band, [radiolabeled
p53(a)]/[total p53(d)]
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oic acid significantly increases LRRK2 expression [43]
with little difference of p53 expression, increasing the
possibility for LRRK2-mediated p53 phosphorylation
(Additional file 2: Figure S2). The differentiated cell lysates
were co-immunoprecipitated with the p53 or LRRK2 anti-
body. The results showed that both LRRK2 and p53 were
specifically co-immunoprecipitated with the correspond-
ing partner protein (Fig. 2a). To measure p53 cellular
phosphorylation level by LRRK2, the cell lysates were
immunoprecipitated with the p53 antibody and detected
with the p-TXR antibody. Transfection of the SH-SY5Y
cells with shLRRK2 or myc-G2019S plasmid significantly
decreased or increased p-TXR levels in the p53 immuno-
precipitates, respectively (Fig. 2b & c). The increase of p53
phosphorylation was also observed in the rat primary
neuron cells overexpressing G2019S and dopaminergic
neurons differentiated from human induced pluripotent
stem (iPS) cells derived from fibroblasts of a G2019S
carrier (Fig. 2d & Additional file 3: Figure S3). We
conducted a similar experiment after treating the cells
with LRRK2-IN-1, the LRRK2 kinase specific inhibitor
[44]. Inhibitor treatment decreased p53 phosphoryl-
ation (Additional file 4: Figure S4A).
Altogether, these results suggest that LRRK2 phos-
phorylates the threonine in the p53 TXR motifs. How-
ever, the high residual activity (>50 %) observed insamples treated with LRRK2-IN-1 suggested that LRRK2
is not the sole kinase phosphorylating such p53 sites al-
though we cannot exclude the possibility that the re-
sidual activity is due to incomplete inhibition of LRRK2
kinase activity in the LRRK2-IN-1 treatment (Additional
file 4: Figure S4A, pS935 in the input panel). In fact,
various kinases such as TFIIH CDK7-cycH-p36 [45],
protein kinase C [46, 47], CHK1, and CHK2 [48] report-
edly phosphorylate at least p53 Thr377.
LRRK2-induced p53 phosphorylation accumulates p53 in
the nucleus and activates p21WAF1/CIP1 expression
p53 is an important transcription factor. Human p53 con-
tains three functional nuclear localization signals (NLSs),
such as 305 ~ 322, 369 ~ 375, and 379 ~ 384([49], Fig. 1C).
We tested whether the structural change, which may be
caused by phosphorylating T304 and T377 sites, could
affect p53 nuclear localization because they are very
close to these NLSs. The SH-SY5Y cell line contains
WT p53, which is located in the cytoplasm and nucleus
[50]. Knocking down of LRRK2 expression by shLRRK2
transfection or ectopic expression of G2019S signifi-
cantly decreased or increased the amount of nuclear
p53 compared to that in the control, respectively
(Fig. 3a & b). The treatment of LRRK2 kinase inhibitor
exhibited a similar result to that of shLRRK2 transfec-
tion (Additional file 4: Figure S4B). These results
Fig. 2 Phosphorylation of Thr in the p53 TXR sites is dependent on LRRK2 kinase activity. a. Interaction between LRRK2 and p53. Lysates
from differentiated SH-SY5Y cell were immunoprecipitated with the indicated antibodies or control antibody, and each immunoprecipitate
(p53IP, LRRK2IP or IgG IP) was subjected to the Western blot with the indicated antibodies. The experiments were carried out three times,
and a representative image is shown. 20 % of input lysates are shown (Input). B & C. Phosphorylation level of Thr in the p53 TXR sites are
proportional to LRRK2 expression level. Differentiated SH-SY5Y cells were transfected with the shLRRK2 (b) or myc-G2019S (c) plasmids for 18 or 24 h,
respectively, and the cell lysates were immunoprecipitated with the p53 antibody. Both the immunoprecipitates (IP: p53) and 20 % or 10 % cell lysates
(Input) of the shLRRK2 or G2019S transfection, respectively, were subjected to Western blot analysis with the indicated antibodies. – indicates
transfection with the empty vector. D. Rat primary neurons over-expressing LRRK2 G2019S increased phosphorylation of Thr in the p53 TXR
sites. The indicated cell lysates were immunoprecipitated with the p53 antibody and the immunoprecipitates (IP: p53) were subjected to Western blot.
Input indicates 20 % of the cell lysates. The experiments were repeated three times, and a representative result is shown with a statistical analysis of
the three results from each experiment, except D which was carried out once. Numbers below the gel figure (d) are relative protein level of each TXR
band ([p-TXR]/[total p53]) based on the densitometric analysis. The antibodies used for Western blot analysis were indicated in the right side of each
blot. *: p <0.05
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causes accumulation of nuclear p53. In addition, immuno-
fluorescence staining assay after ectopic expression of the
p53 WT or phosphomimetic mutant T304/377D proteins
in the differentiated SH-SY5Y cell line also showed that
the number of cells predominantly expressing nuclear p53increased in cells transfected with the mutant p53 com-
pared to those with the p53 WT (Fig. 3c).
Next, we investigated the physiological consequences
of LRRK2-induced p53 phosphorylation. We again uti-
lized LRRK2-IN-1 and plasmids expressing shLRRK2 or
G2019S. After each treatment or transfection, the cells
Fig. 3 LRRK2 kinase activity regulates nuclear localization of p53. Down-regulation of LRRK2 expression by shLRRK2 transfection (a) or over-expressing
G2019S (b) regulates the amount of nuclear p53. Differentiated SH-SY5Y cells were transfected with the indicated plasmids, the cell lysates
were fractionated, and the cytoplasmic and nuclear fractions were subjected to the Western blot with the indicated antibodies. Lamin B and HSP90
were used for nuclear and cytoplasmic markers, respectively. (c) Nuclear localization of p53 protein was increased in the phosphomimetic T304/377D
mutant compared to p53 WT. HA-tagged p53 WT or T304/377D plasmids were transfected to the SH-SY5Y cells, and the cells were immunostained
with DAPI and Alexa 488 (HA). Ten images were taken and the transfected cells were chosen for the analysis (n = 3, Total cell numbers are 143 for the
WT and 118 for the mutant). The localization of p53 protein was blindly determined as nuclear, cytoplasmic, or both, and the number of cells of each
case was counted. Each representative image and the bar graph are shown. # and * indicate cells predominantly expressing cytoplasmic and nuclear
p53, respectively. *: p <0.05
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PCR and Western blot. Transfection of the cells with
shLRRK2 or G2019S resulted in decreased or increased
p21 mRNA and protein levels, respectively (Figs. 4a & b
and 5a & b). We also used reporter plasmids expressing
a luciferase under control of the p21(waf ) promoter to
further confirm the regulation of p21 by LRRK2-mediatedFig. 4 LRRK2 induces p21 transcription in differentiated SH-SY5Y cells. Diffe
18 h (a) or the myc-tagged G2019S for 24 h (b). cDNA was synthesized fro
PCR was carried out using the cDNA as template, with the specific primers
least three times, and a representative result is shown with the statistical an
transfected with shLRRK2, G2019S mutant, or p53 WT and T304/377D. The
***: p <0.001p53 phosphorylation at the transcriptional level [51].
The shLRRK2 transfection decreased luciferase activ-
ity, whereas overexpressing LRRK2 G2019S or the
phosphomimetic p53 T304/377D increased it (Fig. 4c).
In addition, we observed that G2019S-expressing cells
significantly increased cleaved PARP, an apoptotic marker,
and released lactate dehydrogenase (LDH) activity, andrentiated SH-SY5Y cells were transfected with the shLRRK2 plasmid for
m mRNA isolated from the cell lysates in each case. Semi-quantitative
(Table 1) for the indicated genes. All experiments were repeated at
alysis. c. Activity of the p21 promoter-luciferase reporter from cells
experiment was done in nine separate wells in three sets. **: p <0.01;
Fig. 5 (See legend on next page.)
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Fig. 5 LRRK2 mediated p53 phosphorylation induces p21 expression and cytotoxicity in differentiated SH-SY5Y cells. The SH-SY5Y cells were
transfected with the plasmid expressing shLRRK2 (a), G2019S (b), HA-p53, T304/377D and T304/377A (c), HA- T304/377D (D) or FLAG-p21(E).
The p53 T304/377D mutant (d) or p21 (e) were transfected in a dose-dependent manner. The cell lysates were subjected to Western blot with
the indicated antibodies with β-actin or α-tubulin as the loading controls. The transfected cells were also subjected to LDH (cytotoxicity) and/or CCK8
(Cell viability) assay (B ~ E). Actual transfection of each plasmid was confirmed by expression of the corresponding proteins. All experiments
were repeated three times, and a representative Western image and a graphic representation with the statistical analysis are shown. *: p <0.05; **:
p <0.01; ***: p <0.001
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apoptosis-mediated cytotoxicity (Fig. 5b). Treating SH-
SY5Y cells with a LRRK2 kinase inhibitor, LRRK2-IN-1,
exhibited the similar results- decrease of p21 mRNA and
protein levels based on the RT-PCR and Western blot as-
says (Additional file 4: Figure S4C-D). Treatment of the
cells with GSK2578215A, another LRRK2 kinase specific
inhibitor [52], also exhibited decrease of p21 expression
(Additional file 4: Figure S4E). The effectiveness of
LRRK2-IN-1 and shLRRK2 was confirmed by the reduc-
tion in phosphorylated S-935 LRRK2 [44] and LRRK2
mRNA and protein levels, respectively (Figs. 4a and 5a
and Additional file 4: Figure S4A). Besides, exogenous
expression of p53 WT, T304/377D and T304/377A
exhibited increase of p21 expression, cleaved PARP
and cytotoxicity in order of T304/377D >WT ≈ T304/
377A > vector (Fig. 5c). Moreover, direct expression of
the T304/377D or exogenous FLAG-p21 by transfec-
tion also exhibited similar results- increase of p21,
cleaved PARP and cytotoxicity in a dose-dependent
manner (Fig. 5d and e).
In addition, the rat primary neurons transfected with
plasmids expressing myc-G2019S, p53 T304/377D or
FLAG-p21 also exhibited increase of p21, cleaved PARP
and cytotoxicity (Fig. 6 and Additional file 5: Figure S5).
Similar to the SH-SY5Y cells, exogenous expression of
p53 WT, T304/377D and T304/377A in the rat primary
neurons exhibited increase of p21 expression in order of
T304/377D >WT ≈ T304/377A > vector (Figs. 5c vs. 6b).
The Western blot with the G2019S TG mice mid-brain
lysates also revealed that p21 expression in the TG mice
significantly increased compared to that in the non TG
littermates (Fig. 6d).
Altogether, these data suggested the activation of p21
and apoptotic cell death via specific p53 phosphorylation
by LRRK2 kinase activity.Discussion
p53 as a LRRK2 kinase substrate
We found here that LRRK2 phosphorylated p53 on
T304 and T377 using a specific p-TXR antibody
(Fig. 1). We also observed cellular interaction of
LRRK2 with p53 (Fig. 2a). Using the unbiased proteo-
mics approach (Table S1 in [19]), p53 has beenpreviously reported as one of LRRK2 interacting pro-
teins, which supports our data.
In contrast to the Western blot data, the in vitro isotope
kinase assay showed that the T304/377A mutant was still
phosphorylated, although radioactivity decreased consid-
erably compared to that of the WT (Fig. 1A & B). Com-
bined with the Western blot result, our data suggest that
LRRK2 phosphorylates p53 at other sites in addition to
T304 and T377. These sites may occur in the 293 amino
acids N-terminal. In fact, the p53 N-terminus is heavily
phosphorylated, resulting in different effects on p53 func-
tion [35]. Repeated MS analysis of phosphorylated p53
after incubation with LRRK2 failed to reveal such sites,
and the identity of the putative additional site(s) remains
unknown. Therefore, the T304/377D mutant may have
only exhibited a partial effect on LRRK2-mediated p53
phosphorylation, although we used the mutant as a phos-
phomimetic protein in this study. Therefore, we also
employed the treatment of LRRK2 kinase inhibitors, and
transfection of G2019S or shLRRK2 plasmid regulating
the LRRK2 expression level. Regardless of differences in
experimental approaches, corresponding differences in
p21 expression and cleaved PARP level have been com-
monly observed in the differentiated SH-SY5Y cells, rat
primary neurons, G2019S TG mice brain lysates and
dopaminergic neurons differentiated from human iPS cells
of a G2019S carrier (Figs. 5 & 6), suggesting that apoptotic
cell death by LRRK2 [53] was partially mediated through
p53 phosphorylation.
The p53 phosphorylation system is very complex. One
specific kinase phosphorylates multiple p53 sites, and the
same residue can be phosphorylated by multiple kinases
in response to diverse stressors [54]. Phosphorylation of
p53 results in various phenotypes, depending on the site
phosphorylated, such as the changes in binding affinity for
a specific partner protein, the stability or DNA binding af-
finity which usually results in a change in p53 transcrip-
tion activity [35]. The p53 Thr 377 is one of the minor
phosphorylation sites by TFIIH CDK7-cycH-p36 [45] or
protein kinase C [46, 47]. In addition, both CHK1 and
CHK2 phosphorylated Thr377 and Ser378, and 377/378D
phosphomimetic mutation reduced p53 Lys373 acetyl-
ation [48], suggesting a repressed p53 transcriptional ac-
tivity. Our results suggest that LRRK2-mediated p53
phosphorylation increases nuclear localization of p53
Fig. 6 (See legend on next page.)
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Fig. 6 LRRK2 mediated p53 phosphorylation induces p21 expression in lysates of rat primary neurons and midbrain of G2019S TG mice.
Transfection of rat primary neurons with myc-G2019S (a), HA-p53, T304/377D and T304/377A (b) or FLAG-p21(c) was carried out and expression levels
of p21 were detected by Western blot analysis. The cells transfected with FLAG-p21 were also subjected to LDH assay to measure cytotoxicity (c). The
experiments were repeated three (a, c) or four (b) times, and a representative result is shown with the statistical analysis. d. The midbrain lysates of
G2019S TG or corresponding littermate mice were subjected to the Western blot with the indicated antibodies (n = 3). *: p <0.05; ***: p <0.001
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discrepancy in the results [48] may be because each kinase
phosphorylates other specific sites in addition to T377.
In contrast to T377, phosphorylation on Thr304 has
been reported in endogenous p53 in human foreskin
fibroblasts treated with the p53 activating chemical,
etoposide [55]. However, physiological function of this
phosphorylation is unknown.
Physiological consequences of p53 phosphorylation by
LRRK2
p53 is a well-characterized transcription factor activating
multiple genes that mediate apoptosis and cell growth ar-
rest in response to various genotoxic and non-genotoxic
stressors. We initially tested the effect of LRRK2-induced
p53 phosphorylation on its target genes, p21 and MDM2,
by RT-PCR and Western blot analyses. The results suggest
that LRRK2-induced p53 phosphorylation activates ex-
pression of p21 (Figs. 4, 5 and 6) but not that of MDM2.
MDM2 expression was changed to a pattern similar to
that of p21, under some conditions, but the difference was
not significant (data not shown).
P21WAF1/CIP1 (p21) is a cell growth inhibitor activated
by p53 [56]. The functions of p21 in cell proliferation
and neuronal cell toxicity are controversial. The induc-
tion of p21 is required for neuron survival [57]. However,
increased p21 expression induced by p53 phosphorylation
inhibits proliferation of embryonic neuronal cells [58]. An-
other study reported that p53 induces p21 expression and
apoptosis in neuroblastoma cells [59]. In addition, DNA-
damaging drug treatment induces p53 and p21 expression
and results in apoptosis in SH-SY5Y cells [60]. In our
study, LRRK2-mediated p53 phosphorylation in differenti-
ated SH-SY5Y cells and primary neurons significantly in-
creased p21 expression and cytotoxicity (Figs. 4, 5 and 6).
This result was repeatedly confirmed under various condi-
tions, such as ectopic expression of phosphomimetic
T304/377D or G2019S mutants, treatment of two differ-
ent LRRK2 kinase inhibitors, down-regulation of LRRK2
expression level by shLRRK2 transfection, and G2019S
TG brain lysates (Figs. 4, 5 and 6 and Additional file 4:
Figure S4). More importantly, ectopic expression of p21
itself in differentiated SH-SY5Y cells and rat primary
neurons suggested that p21 activation in these cells results
in apoptosis (Figs. 5e & 6c). We also tested the effect of
p53 T304/377D expression in the human colon cancer
HCT116 p53 null cell line. In contrast to differentiatedSH-SY5Y cells, no p21 expression was observed in the
promoter and Western blot assays of the HCT cell line,
suggesting that the effect we observed may be a cell-type,
perhaps a neuron-specific one (data not shown).
Transfection of the phosphomimetic p53 T304/377D
mutant exhibited increase of p21 expression whereas
transfection of the T304/377A mutant that was unable
to be phosphorylated showed lower p21 expression,
similar to that of the WT (Figs. 5c & 6b). The reason
why the T304/377A mutant still contains the activity
similar to the WT might be because the T304/377A mu-
tant can be still phosphorylated by other kinases at add-
itional sites, like the WT.
Involvement of p53 in PD pathogenesis has been sug-
gested in several reports, showing that the expression of
p53 is higher in PD brains than in non-PD brains and that
several PD-causing chemicals, such as rotenone and 6-
hydroxydopamine, activate p53 [61–67]. In addition, rote-
none induces upregulation of p53, p38, phospho-p38, and
Bax in cultured PC12 cells and rats [67]. Several studies
investigating PD-causative genes revealed that p53 is an
important regulator of PD. For example, parkin and p53
reciprocally regulate each other in a cell-specific manner.
p53 is a transcriptional activator of Parkin in cancer cells
[68], and Parkin is a p53 transcriptional repressor in neur-
onal cells [62]. In addition, cytosolic p53 inhibits mito-
phagy mediated by Parkin in mouse hearts [69]. However,
these transcriptional regulations were observed in a cell-
specific manner [69], as in our data showing differences in
p21 activation between the SH-SY5Y and HCT116 p53
null cell lines. Two other PD-recessive genes, DJ-1 and
PINK1, also regulate p53 functions [37, 70].
Because p53 is one of the most important tumor sup-
pressors, the physiological consequence of p53 phos-
phorylation by LRRK2 related to cancer is a critical
question. Our Western data show increase in p21 and
cleaved PARP protein levels and cytotoxicity of G2019S
overexpressing cells. The low incidence of most cancers,
excluding melanoma, in patients with PD has been well-
documented in several epidemiological studies [71–73].
Our data provide a possible mechanism for this observa-
tion- i.e., increase of LRRK2 kinase activity inducing p53
phosphorylation and increasing p21 expression and cyto-
toxicity in most tissues- which is probably making cells
more susceptible to p53-activating stimuli and evading
cancer. However, a contradictory study showed that
LRRK2 gene amplification causes a certain types of
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In addition, there are contradictory reports about the ef-
fect of the G2019S mutation on the cancer [75, 76].
More studies are required to explain this discrepancy. In
addition, it remains to be determined whether our obser-
vation is directly related to a PD pathogenic mechanism
by a LRRK2 G2019S mutation and which stimuli activate
LRRK2 kinase activity related to p53.
Conclusions
LRRK2, a PD causative gene, phosphorylates p53 at
T304 and T377 residues. Phosphorylation of p53 by
LRRK2 increases p53 nuclear localization, expression of
p21WAF1/CIP1, cleaved PARP level, and cytotoxicity in dif-
ferentiated SH-SY5Y cells and rat primary neurons.
Methods
Plasmids and recombinant proteins
Plasmids expressing the HA-tagged human p53 gene
(16434) and FLAG-p21 (16240) were purchased from
Addgene (Cambridge, MA, USA) and shLRRK2 plasmid
specifically inhibiting expression of endogenous human
LRRK2 (TI202451) from ORIGENE (Rockville, MD,
USA). The pET28 bacterial vector (Novagen, Darm-
stadt, Germany) expressing histidine tagged full length
p53 [His-p53(1–393 amino acids)], and deleted p53,
[His-p53(1–293 amino acids)], were previously reported
[58]. The indicated p53 mutations were introduced by
in vitro site-directed mutagenesis with proper primer
pairs, and their sequences were confirmed by sequen-
cing the full length of the cloned open reading frame.
LRRK2 and its mutant plasmids were constructed as de-
scribed previously [31, 77]. The recombinant LRRK2 WT,
G2019S, and D1994A proteins with or without the N-
terminal 970 amino acids were purchased from Invitrogen
(Carlsbad, CA, USA). The following antibodies were used:
LRRK2 (ab133474 [MJFF2]; Abcam, Cambridge, MA,
USA, 1:1000), p53 (for human p53: sc-126, Santa Cruz
Biotechnology, Dallas, TX, USA, 1:1000 and #2527S, Cell
Signaling Technology, Danvers, MA, USA, 1:500; for
mouse p53: sc-1312, Santa Cruz Biotechnology, 1:100; for
immunoprecipitation of mouse p53: ab26, Abcam,),
p21 (sc-397, Santa Cruz Biotechnology, 1:100), pS935
(ab133450, Abcam, 1:500), Lamin B (sc-6217, Santa
Cruz Biotechnology, 1:500), LDH (sc-33781, Santa
Cruz Biotechnology, 1:500), β-actin (sc-47778, Santa
Cruz Biotechnology, 1:1000), p-TXR (#2351S, Cell
Signal Technology, 1:500), hsp90 (610418, BD transduc-
tion Laboratories, Bedford, MA, USA, 1:5000) α-tubulin
(T5168, Sigma-Aldrich, St. Louis, MO, USA, 1:2500).
The p-TXR antibody, which recognizes PKC-mediated
phosphorylation motif [78] was used to detect phospo-
p53 phosphorylated on the p-TXR motif threonine
residue.Cell culture and transfection
Human SH-SY5Y cells were cultured in DMEM contain-
ing 10 % fetal bovine serum at 37 °C with 5 % CO2 and
differentiated in medium containing all-trans retinoic
acid (10 μM) for 6–7 days to obtain dopaminergic
neuron-like properties.
Rat primary cortical neuron cultures were carried out
as described previously [31]. The LRRK2 specific kinase
inhibitors LRRK2 IN-1 (438193, Merck Millipore,
Darmstadt, Germany) and GSK2578215A (4629, Tocris
Biosciences, Bristol, United Kingdom) was added as in-
dicated. Transfection of plasmid was carried out with
Lipofectamine LTX (Invitrogen) as recommended by
the manufacturer.
In vitro kinase assay
We used the N-terminal truncated protein fused to GST
or full length recombinant LRRK2 protein (Invitrogen),
for the LRRK2 in vitro kinase assay. Protein (50 ng) was
used for each kinase reaction. The indicated proteins
were incubated in 20 μl kinase buffer [2.5 μCi of γ32P-
ATP (BLU502; Perkin Elmer, Waltham, MA, USA),
50 μM ATP, 25 mM Tris–HCl (pH 7.5), 5 mM β-
glycerol phosphate, 2 mM DTT, 0.1 mM NA3VO4 and
10 mM MgCl2] containing approximately 100 ng of the
indicated proteins at 30 °C for 20 min. p53 WT or mu-
tant proteins were expressed and purified from the E.
coli BL21 strain. The samples were subjected to sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and
the dried gel was analyzed by autoradiography.
Reprogramming of human fibroblasts to induced
pluripotent stem cells and their differentiation to
dopaminergic neurons
Normal human fibroblast (IMR-90, ATCC) and Parkin-
son’s disease patient fibroblasts with LRRK2-G2019S
mutation (#ND29492, Coriell Cell Repositories, Camden,
NJ, USA) were reprogrammed to induced pluripotent
stem cells (iPSCs) as described in previous report [79]
with some modifications. In detail, the vectors were intro-
duced using the Neon (Invitrogen) and the reprogram-
ming medium was supplemented with 0.5 μM A83-01
(Tocris, Bristol, UK), 3 μM CHIR99021 (Tocris), and
0.2 mM sodium butyrate (Sigma).
The use of human cells and human pluripotent stem
cells (hPSCs) were reviewed by institutional review board
of KRIBB and we followed the guidelines in all experi-
ments. The hPSCs were differentiated to neuroectoder-
mal spheres (NES) as described previously [80]. For the
dopaminergic neuronal differentiation, NESs that were
cultured for four days after passaging were placed in dopa-
minergic neural patterning medium (DPM; DMEM/F12,
N2 supplement (1:100), B27 supplement (1:50), 100 U/ml
penicillin-streptomycin (all from Invitrogen), 100 ng/ml
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3 μM CHIR99021 (Tocris) and 0.2 mM 2-Phospho-L-as-
corbic acid (Sigma)) for four days. Patterned NESs were
dissected by McIlwain tissue chopper and attached on
matrigel-coated culture dishes. After four days, DPM was
replaced by terminal differentiation medium (TDM;
DMEM/F12, N2 supplement (1:100), B27 supplement
(1:50), 100 U/ml penicillin-streptomycin, 20 ng/ml BDNF,
20 ng/ml GDNF, 0.5 mM dibutyryl-cAMP (Enzo, Farm-
ingdale, NY, USA), and 0.2 mM 2-Phospho-L-ascorbic
acid (Sigma)). All cytokines were obtained from Peprotech
(Rocky Hill, NJ, USA). To get differentiated neurons, half
of TDM was replaced every two days until 2 weeks.
The lysates of the differentiated neurons were immu-
noprecipitated with p53 antibody and were subjected to
the western blot analysis with p-TXR antibody to inves-
tigate the level of phospho-Threonine at TXR of p53.Immunoprecipitation, nuclear fractionation and Western blot
The cell lysates were centrifuged at 16,000 × g for
10 min at 4 °C to remove insoluble material. The super-
natants were precleared, then immunoprecipitated with
anti-p53 or anti-LRRK2 (MJFF2, Abcam) at 4 °C for 8 h,
and further incubated with protein-A agarose (Pierce,
Rockford, IL,USA) for 24 h. The antibody-protein com-
plexes were subjected to Western blot analysis using the
indicated antibodies.
Cell nuclei were fractionated using a Nuclear/Cytosol
Fractionation kit (K266-100, Bioscience, Milpitas, CA,
USA) as suggested by the manufacturer, after the indi-
cated treatment.
G2019S TG mice (#009609, Jackson Laboratory, Bar
Harbor, ME, USA) and normal control littermates
were sacrificed by cervical dislocation. Brain tissues
were disrupted using a Dounce Homogenizer (10
strokes) and lysed by passing the extracts through a
22-gauge needle five times. The brain lysates were
centrifuged at 16,000 × g for 30 min at 4 °C toTable 1 The primers used in the RT-PCR assays
Primer name Gene Direction Sequence
hP21-F P21 Forward GTTCCTTGG
hP21-R Reverse GGTACAAG
LRRK2-7232 LRRK2 Forward GTCATGATG
LRRK2-7440 Reverse CTCTTACTC
pMycXhoI-R Myc tag Reverse CTTCTGAGA
b-actin-F β-actin Forward CGCCGCCA
b-actin-R Reverse CACGATGG
The polymerase chain reaction was carried out at 95 °C for 1 min and 35 cycles of 9
aThe pMycXhoI-R primer was used with LRRK2-7232 to detect expression of Myc-LR
Bp base pairsremove insoluble material, and supernatants were used for
further Western blot analysis.
The immunoprecipitated antibody-protein complexes,
cell or brain lysates, or fractionated samples were subjected
to Western blot analysis using the indicated antibodies.
Luciferase assay and reverse transcription –polymerase
chain reaction (RT-PCR)
Differentiated SH-SY5Y cells were transfected with the
indicated reporter plasmids. The shLRRK2 plasmid was
co-transfected with the reporter plasmid to knock down
LRRK2 expression. The luciferase assay was conducted
using the Dual Luciferase Assay kit (Promega, Madison,
WI, USA). pRL-TK was co-transfected to normalize
transfection efficiency.
Total RNA was isolated from the indicated cells, used
for cDNA synthesis, and the target mRNAs were ampli-
fied by PCR using the cDNAs as templates and the indi-
cated primer sets under the indicated conditions
(Table 1). The PCR products were analyzed by agarose
gel analysis.
Confocal microscopy
Differentiated SH-SY5Y cells were transfected with
HA-tagged p53 WT, T304/377D, or empty vector.
After incubation, cell were sequentially immunostained
with HA antibody and Alexa Fluoro 488 secondary anti-
body (Invitrogen) and the nuclei were counterstained with
4',6-diamidino-2-phenylindole (DAPI). The experiments
were repeated to prepare three sets. Each set was observed
under a Zeiss LSM700 confocal microscope and ten im-
ages were randomly taken. Predominant localization of
p53 protein was scored blindly as nuclear, cytosol or both
and the number of cells in each case was counted.Statistical analysis
All statistical analysis was carried out with the Prism5
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Additional file 1: Figure S1. LRRK2 phosphorylates p53 and moesin at
TXR sites in the in vitro kinase assay. A. Phosphorylation of various p53
proteins by the Flag-tagged full length LRRK2 protein (Invitrogen) after the
in vitro kinase assay. Phosphorylated p53 was detected by either
autoradiography or Western blot with the p-TXR antibody. B. Western blot
analysis after the in vitro kinase assay using moesin, various GST-ΔN-LRRK2
WT and mutant proteins, and cold ATP. (DOC 88 kb)
Additional file 2: Figure S2. Differentiating SH-SY5Y cells with retinoic
acid induces LRRK2 expression with little difference of p53. Indicated
concentration of all- trans-retinoic acid was treated for two days. (DOC 65 kb)
Additional file 3: Figure S3. Increased phosphorylation of Thr in the
p53 TXR sites in dopaminergic neurons differentiated from fibroblast-derived
iPS cells that were obtained from the human G2019S carrier (WT/GS) and
non-carrier (WT/WT). The indicated cell lysates were immunoprecipitated with
the p53 antibody and the immunoprecipitates (IP: p53) were subjected to
Western blot. Input indicates 20% of the cell lysates. Numbers below the gel
figures are relative protein level of each TXR band ([p-TXR]/[total p53]) based
on the densitometric analysis. The antibodies used for Western blot analysis
were indicated in the right side of each blot. (DOC 57 kb)
Additional file 4: Figure S4. LRRK2 kinase inhibitor decreased p21
expression. Differentiated SH-SY5Y cells were treated with 1 μM LRRK2-IN-1
for 2 h (A-D) or 0.5 μM GSK2578215A (Tocris Biosciences, Bristol, United
Kingdom) for 12 h (E). The p53 immunoprecipitates of the cell lysates were
used to detect p-TXR level (A). The LRRK2-IN-1 treated cells were also
used to determine relative amount of nuclear p53 (B) as in Fig. 3a.
The cell lysates were used to detect p21 mRNA (C) and protein (D)
levels as in Figs. 4 and 5. p21 expression level of GSK2578215A treated cells
were also tested (E). Activities of LRRK2 kinase inhibitor treatments
were confirmed by reduced level of LRRK2 p935 (pS935). – indicates
vehicle treatment. Lamin B and LDH were used for nuclear and cytosolic
markers, respectively. All experiments were repeated three times, and
a representative result is shown with a bar graph. *: p <0.05; **: p <0.01.
(DOC 188 kb)
Additional file 5: Figure S5. Expression of T304/377D mutant increased
cytotoxicity in rat primary neurons. The neuronal cells were transfected with
vector, HA-p53, T304/377D and T304/377A. The cytotoxicity was measured
by LDH assay. n = 6. **: p <0.01; ***: p <0.001. (DOC 49 kb)
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